The once-monthly drug is still under study but could provide added convenience and another option for patients.

Hundreds of people have reported problems with their pancreas after taking GLP-1 agonists, including ten deaths.

Since the GLP-1 drugs, including Mounjaro, Ozempic and Wegovy, were licensed, there have been hundreds of reported cases of acute and chronic pancreatitis among people taking them, figures from the UK ...

GP in many parts of England are having explain to eligible patients that tirzepatide (Mounjaro) cannot be prescribed in ...

Three months since Suzanne Harrington was prescribed the weight-loss jab Mounjaro, she opens up her diary and reveals all ...

In a new TikTok video, the consultant and professor explains who's really eligible and why BMI isn't the full story ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...

A woman says she was diagnosed with potentially life-threatening pancreatitis less than two months after starting to take the ...